Topic

Dr. Bethany Valente is the founder and managing partner of 

Articles

Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.










Making the Most of the Rising Biopharma M&As

Pharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.

Purposeful Partnerships for Post-COVID Era

Amgen board member and serial CEO Fred Hassan talks about the three levers  Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Digital Transformation: A Journey, Not Just a Destination

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?

SPACs: From Fad to Fixture: COVID Sparks Greater Use of IPO Alternative

NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.

Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing Needs

Focusing on prevention, diagnosis, treatment, and care monitoring during the patient journey in oncology to create value for stakeholders.

Uncover Potential Life Cycle Opportunities in Oncology Using Patient-Centric Outcomes

What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.

The Amazon Effect: A Data-Fueled Customer Experience 

Dr. Wolfram Lux is a Senior Director in the global Pharma & Biotech practice within Simon-Kucher & Partners Life Sciences Division.

Dr. Simone Seiter is a Partner at Simon-Kucher and is based in Frankfurt where she works for the global Pharma & Biotech practice within the Life Sciences division.

Christian M. Hinneburg is Consultant in Life Sciences at Simon-Kucher & Partners.

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.

Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime Value

How engaging with digital influencers holds the key for medical affairs.

Bridging the Generational Chasm in Oncology

Gabriela Marton is Regulatory Affairs Director and Quality Director at Arriello, where she leads the regulatory affairs functions, developing robust and efficient market access and post-marketing strategies to support pharmaceutical companies’ business needs. She has over 14 years’ experience in regulatory affairs and compliance within the pharmaceutical and food supplements sectors. Previously, she was an independent regulatory consultant, and has held several positions in regulatory affairs and compliance in various pharmaceutical companies, one of which is GSK where she started her regulatory career and worked for almost a decade.

If the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.

Strategy